Cargando…

A comparison of misoprostol with and without methylergometrine and oxytocin in outpatient medical abortion: a phase III randomized controlled trial

OBJECTIVE: The complications associated with miscarriages have surfaced as a major concern in maintaining women’s physical and mental health. The present study evaluated the efficacy of three medication regimes for the complete expulsion of retained intrauterine tissues in patients who underwent a m...

Descripción completa

Detalles Bibliográficos
Autores principales: Jahromi, Athar Rasekh, Rahmanian, Vahid, Taghizadeh, Hajar, Zareibabaarabi, Zahra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557307/
https://www.ncbi.nlm.nih.gov/pubmed/37798748
http://dx.doi.org/10.1186/s13104-023-06509-6
_version_ 1785117062368067584
author Jahromi, Athar Rasekh
Rahmanian, Vahid
Taghizadeh, Hajar
Zareibabaarabi, Zahra
author_facet Jahromi, Athar Rasekh
Rahmanian, Vahid
Taghizadeh, Hajar
Zareibabaarabi, Zahra
author_sort Jahromi, Athar Rasekh
collection PubMed
description OBJECTIVE: The complications associated with miscarriages have surfaced as a major concern in maintaining women’s physical and mental health. The present study evaluated the efficacy of three medication regimes for the complete expulsion of retained intrauterine tissues in patients who underwent a miscarriage. METHODS: In this randomized clinical trial, 90 patients participated with their gestational age below 12 weeks, each having undergone a recent miscarriage. After being screened for underlying diseases and coagulative blood disorders, they were randomly allocated into three groups. For the first group, labeled as the control group, misoprostol was administered alone. In contrast, the combination of misoprostol plus methylergometrine and misoprostol plus oxytocin was prescribed for the second and third groups, respectively. Further, the data obtained were analyzed by descriptive and inferential statistics using Stata software version 14. RESULTS: The mean age of participants and gestational age were 29.76 ± 5.53 years and 8.23 ± 2.29 weeks, respectively. There was no significant difference between the three treatment groups regarding the amount of bleeding after the abortion(P = 0.627). Regarding pain severity, the group that received Misoprostol plus Methylergometrine had less pain intensity than the other two groups(p = 0.004). The mean rate of RPOC expulsion was in the Misoprostol plus Oxytocin (9.68 ± 10.36) group, Misoprostol plus Methylergometrine (11.73 ± 12.86), and Misoprostol groups (19.07 ± 14.31)(p = 0.013). The success rate in outpatient medical abortion in the misoprostol plus oxytocin and misoprostol plus methylergonovine group was 93.33%, but in patients treated by misoprostol alone was 83.33%. CONCLUSION: The effectiveness of the drugs in the two drug groups combined with oxytocin and methylergometrine is higher than the misoprostol group alone. An outpatient approach was deemed more satisfactory against surgical maneuvers and hospitalizations by patients since family support influenced their pain coping mechanism. TRIAL REGISTRATION: The trial was registered in the Iranian registry of clinical trials on 04/10/2019. (https://fa.irct.ir/trial/34519; registration number: IRCT20150407021653N19).
format Online
Article
Text
id pubmed-10557307
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105573072023-10-07 A comparison of misoprostol with and without methylergometrine and oxytocin in outpatient medical abortion: a phase III randomized controlled trial Jahromi, Athar Rasekh Rahmanian, Vahid Taghizadeh, Hajar Zareibabaarabi, Zahra BMC Res Notes Research Note OBJECTIVE: The complications associated with miscarriages have surfaced as a major concern in maintaining women’s physical and mental health. The present study evaluated the efficacy of three medication regimes for the complete expulsion of retained intrauterine tissues in patients who underwent a miscarriage. METHODS: In this randomized clinical trial, 90 patients participated with their gestational age below 12 weeks, each having undergone a recent miscarriage. After being screened for underlying diseases and coagulative blood disorders, they were randomly allocated into three groups. For the first group, labeled as the control group, misoprostol was administered alone. In contrast, the combination of misoprostol plus methylergometrine and misoprostol plus oxytocin was prescribed for the second and third groups, respectively. Further, the data obtained were analyzed by descriptive and inferential statistics using Stata software version 14. RESULTS: The mean age of participants and gestational age were 29.76 ± 5.53 years and 8.23 ± 2.29 weeks, respectively. There was no significant difference between the three treatment groups regarding the amount of bleeding after the abortion(P = 0.627). Regarding pain severity, the group that received Misoprostol plus Methylergometrine had less pain intensity than the other two groups(p = 0.004). The mean rate of RPOC expulsion was in the Misoprostol plus Oxytocin (9.68 ± 10.36) group, Misoprostol plus Methylergometrine (11.73 ± 12.86), and Misoprostol groups (19.07 ± 14.31)(p = 0.013). The success rate in outpatient medical abortion in the misoprostol plus oxytocin and misoprostol plus methylergonovine group was 93.33%, but in patients treated by misoprostol alone was 83.33%. CONCLUSION: The effectiveness of the drugs in the two drug groups combined with oxytocin and methylergometrine is higher than the misoprostol group alone. An outpatient approach was deemed more satisfactory against surgical maneuvers and hospitalizations by patients since family support influenced their pain coping mechanism. TRIAL REGISTRATION: The trial was registered in the Iranian registry of clinical trials on 04/10/2019. (https://fa.irct.ir/trial/34519; registration number: IRCT20150407021653N19). BioMed Central 2023-10-05 /pmc/articles/PMC10557307/ /pubmed/37798748 http://dx.doi.org/10.1186/s13104-023-06509-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Note
Jahromi, Athar Rasekh
Rahmanian, Vahid
Taghizadeh, Hajar
Zareibabaarabi, Zahra
A comparison of misoprostol with and without methylergometrine and oxytocin in outpatient medical abortion: a phase III randomized controlled trial
title A comparison of misoprostol with and without methylergometrine and oxytocin in outpatient medical abortion: a phase III randomized controlled trial
title_full A comparison of misoprostol with and without methylergometrine and oxytocin in outpatient medical abortion: a phase III randomized controlled trial
title_fullStr A comparison of misoprostol with and without methylergometrine and oxytocin in outpatient medical abortion: a phase III randomized controlled trial
title_full_unstemmed A comparison of misoprostol with and without methylergometrine and oxytocin in outpatient medical abortion: a phase III randomized controlled trial
title_short A comparison of misoprostol with and without methylergometrine and oxytocin in outpatient medical abortion: a phase III randomized controlled trial
title_sort comparison of misoprostol with and without methylergometrine and oxytocin in outpatient medical abortion: a phase iii randomized controlled trial
topic Research Note
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557307/
https://www.ncbi.nlm.nih.gov/pubmed/37798748
http://dx.doi.org/10.1186/s13104-023-06509-6
work_keys_str_mv AT jahromiatharrasekh acomparisonofmisoprostolwithandwithoutmethylergometrineandoxytocininoutpatientmedicalabortionaphaseiiirandomizedcontrolledtrial
AT rahmanianvahid acomparisonofmisoprostolwithandwithoutmethylergometrineandoxytocininoutpatientmedicalabortionaphaseiiirandomizedcontrolledtrial
AT taghizadehhajar acomparisonofmisoprostolwithandwithoutmethylergometrineandoxytocininoutpatientmedicalabortionaphaseiiirandomizedcontrolledtrial
AT zareibabaarabizahra acomparisonofmisoprostolwithandwithoutmethylergometrineandoxytocininoutpatientmedicalabortionaphaseiiirandomizedcontrolledtrial
AT jahromiatharrasekh comparisonofmisoprostolwithandwithoutmethylergometrineandoxytocininoutpatientmedicalabortionaphaseiiirandomizedcontrolledtrial
AT rahmanianvahid comparisonofmisoprostolwithandwithoutmethylergometrineandoxytocininoutpatientmedicalabortionaphaseiiirandomizedcontrolledtrial
AT taghizadehhajar comparisonofmisoprostolwithandwithoutmethylergometrineandoxytocininoutpatientmedicalabortionaphaseiiirandomizedcontrolledtrial
AT zareibabaarabizahra comparisonofmisoprostolwithandwithoutmethylergometrineandoxytocininoutpatientmedicalabortionaphaseiiirandomizedcontrolledtrial